Chamber Secures $60M in Series A for Cardiology Data Platform

There is a moment in every serious market where the noise drops out and you can hear the machinery underneath. Cardiology is having that moment. The stakes are massive, the spend is relentless, and the outcomes have been historically uneven. Enter Chamber, a company built in 2022 that did not come to admire the problem. Chamber came to operate on it, calmly, precisely, without theatrics.

Chamber just closed a $60M Series A, and the room matters. Frist Cressey Ventures led it, with General Catalyst, AlleyCorp, American Family Ventures, Company Ventures, Optum Ventures, Healthworx Ventures, and Black Opal Ventures leaning in. HSBC Innovation Banking backed the debt. Capital follows clarity, and this table is a signal that cardiology value based care is no longer a theory experiment. It is infrastructure.

George Aloth, Sameer Sheth, MD, and Jeffrey De Flavio, MD built Chamber with the kind of resumes that usually stay in slide decks. Health plans, value based operators, academic medicine, and real clinical scars. George Aloth understands the payer balance sheet. Sameer Sheth, MD understands the patient heartbeat. Jeffrey De Flavio, MD understands how platforms actually scale when incentives get messy. That triangle matters.

Chamber is not selling cardiology software. They are building a chamber of pressure where cardiologists can finally practice value based care without drowning in manual chart review or chasing phantom care gaps. A cloud based platform, workflow native AI, guideline driven pathways, real time hospital signals, and population level visibility that lets 500+ cardiologists across 7 states focus on risk that is real, not theoretical.

The quiet flex is how the system fits into existing practice and payer reality. Direct EHR and claims integration. Care teams collaborating without duct tape. Automated risk assessments that surface patients before the event, not after the invoice. This is not about dashboards that look good in demos. This is about changing the total cost curve of the largest disease category in American healthcare.

Business lesson here is simple and uncomfortable. Chamber earned this round by respecting the operator, the clinician, and the balance sheet at the same time. No cosplay innovation. No loud promises. Just execution that compounds. If you are a cardiologist, a health plan, or anyone serious about cardiovascular outcomes, this is a chamber worth stepping into.